What are the typical symptoms of Multiple System Atrophy (MSA)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 28, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Typical Symptoms of Multiple System Atrophy (MSA)

Multiple System Atrophy (MSA) is characterized by a combination of parkinsonian, autonomic, cerebellar, and pyramidal signs that typically present in adults between 55-65 years of age with rapid progression of disability.

Clinical Presentation by System

Autonomic Dysfunction

  • Autonomic symptoms are initial features in 41% of patients and eventually develop in 97% of cases 1
  • Common manifestations include:
    • Orthostatic hypotension (present in 68% of patients, severe in 15%) 1
    • Urogenital dysfunction:
      • Men: Erectile dysfunction (often the earliest autonomic symptom) 2
      • Women: Urinary incontinence 1
    • Bladder dysfunction: Urinary retention, incontinence (very common) 3
    • Gastrointestinal symptoms: Constipation, alternating diarrhea and constipation 4

Motor Symptoms

  • Parkinsonian features (present in 91% of patients, initial feature in 46%) 1:

    • Akinesia and rigidity (predominant)
    • Asymmetric presentation (74% of cases)
    • Rest tremor (29% of patients, but classical pill-rolling tremor in only 9%)
    • Poor or unsustained response to levodopa (only 13% maintain good response) 1
  • Cerebellar symptoms (develop in 52% of patients, initial feature in 5%) 1:

    • Ataxic gait
    • Dysarthria (slurred speech)
    • Limb ataxia
    • Nystagmus
  • Pyramidal signs (present in 61% of patients) 1:

    • Hyperreflexia
    • Extensor plantar responses
    • Spasticity

Sleep Disorders

  • REM sleep behavior disorder (RBD):
    • Characterized by abnormal behaviors during REM sleep (talking, shouting, gesturing, flailing arms, punching, kicking) 4
    • Often precedes motor symptoms by years
    • Present in approximately 70% of MSA patients 4

MSA Subtypes

MSA-P (Parkinsonian Type)

  • Predominant parkinsonian features (82% of cases) 1
  • MRI findings: Putaminal atrophy, hypointensity on T2-weighted images 5

MSA-C (Cerebellar Type)

  • Predominant cerebellar syndrome (18% of cases) 1
  • MRI findings: Cerebellar and pontine atrophy, "hot cross bun" sign, middle cerebellar peduncle hyperintensity 5

Disease Progression

  • Rapid progression: >40% of patients become markedly disabled or wheelchair-bound within 5 years of motor symptom onset 1
  • Median survival: 9.5 years from symptom onset 1
  • Recurrent urinary tract infections: Major cause of morbidity and mortality (approximately 25% die of related complications) 2

Diagnostic Considerations

  • MRI brain is the optimal imaging modality (3T preferable over 1.5T) 5
  • Cardiovascular autonomic testing to document orthostatic hypotension 5
  • Urodynamic studies to evaluate bladder dysfunction 5
  • DaTscan shows decreased radiotracer uptake in the striatum but cannot differentiate MSA from other parkinsonian syndromes 5

Key Diagnostic Pitfalls

  • MSA symptoms may be confused with Parkinson's disease but differ in:
    • Poor/unsustained levodopa response
    • Early autonomic failure
    • More rapid progression
  • Urological symptoms may be confused with benign prostatic hyperplasia, potentially leading to unnecessary surgery 2
  • Symptoms can fluctuate and evolve over time, requiring ongoing reassessment

Red Flags for MSA

  • Early autonomic failure with parkinsonism
  • Rapid progression of disability
  • Poor response to levodopa or early development of levodopa complications
  • REM sleep behavior disorder preceding motor symptoms
  • Inspiratory stridor

Understanding these typical symptoms is crucial for early diagnosis and appropriate management of MSA, which significantly impacts morbidity, mortality, and quality of life.

References

Research

Management of multiple system atrophy: state of the art.

Journal of neural transmission (Vienna, Austria : 1996), 2005

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Multiple System Atrophy Diagnosis and Evaluation

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.